Table 2 Otologic characteristics of patients with MEE (n = 23)
Characteristics | Median (IQR) or No. (%) |
|---|---|
Age at onset of ear symptoms, years | 45 (35–65) |
Time from EGPA diagnosis to ear symptoms, years | 3.6 (1.0–7.9) |
History of MEE before diagnosis | 5 (21.7) |
Maintenance steroid dose before ear symptoms | |
Prednisolone ≥ 10 mg | 4 (17.4) |
Prednisolone 5–10 mg | 9 (39.1) |
Prednisolone < 5 mg | 3 (13.0) |
None | 7 (30.4) |
Types of ear symptoma | |
Ear fullness | 16 (69.6) |
Hearing loss | 12 (52.2) |
Tinnitus | 7 (30.4) |
Otorrhea | 6 (26.1) |
Otalgia | 4 (17.4) |
Severity of hearing loss (n = 15) | |
Left | |
Normalb | 8 (53.3) |
Mild hearing loss | 5 (33.3) |
Moderate hearing loss | 2 (13.3) |
Right | |
Normalb | 6 (40.0) |
Mild hearing loss | 5 (33.3) |
Moderate hearing loss | 4 (26.7) |
Type of hearing loss (n = 12) | |
Conductive hearing loss | 10 (83.3) |
Mixed hearing loss | 2 (16.7) |
Treatment regimen for MEE | |
Myringotomy/VT insertion + IT injection + systemic steroid dose increase | 7 (30.4%) |
Myringotomy/VT insertion + systemic steroid dose increase | 3 (13.0%) |
IT injection + systemic steroid dose increase | 1 (4.3%) |
Steroid dose increase | 6 (26.1%) |
Myringotomy/VT insertion | 3 (13.0%) |
No treatment | 3 (13.0%) |
Recurrence of the ear symptoms | 9 (39.1) |